UroGen Pharma Balance Sheet
NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
UroGen Pharma financial position
At the end of fiscal 2025, UroGen Pharma reported total assets of $200.5 million, down 29.8% from a year earlier against total liabilities of $305.9 million. Shareholders' equity was negative at -$105.5 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $110.7 million in cash and equivalents against $122.2 million of debt, a net debt position of $11.5 million.
The current ratio (current assets divided by current liabilities) was 4.01, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
UroGen Pharma balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 110.75M | 171.99M | 95.00M | 55.41M | 44.36M | 52.86M | 49.69M | 101.32M | 37.00M | 21.36M |
| Short-Term Investments | 49.31M | 110.67M | 56.16M | 44.56M | 44.78M | 49.15M | 97.39M | — | 36.00M | — |
| Receivables | 33.08M | 20.30M | 15.44M | 12.70M | 11.72M | 7.05M | — | — | — | 83.00K |
| Inventory | 16.46M | 9.23M | 5.67M | 4.33M | 4.83M | 1.96M | — | — | 316.00K | 105.00K |
| Total Current Assets | 186.02M | 276.13M | 169.19M | 128.91M | 114.39M | 115.62M | 148.63M | 102.24M | 74.47M | 22.04M |
| Property, Plant & Equipment | 637.00K | 655.00K | 689.00K | 1.30M | 1.97M | 2.05M | 977.00K | 948.00K | 805.00K | 741.00K |
| Long-Term Investments | 0 | 5.02M | 4.50M | 0 | 675.00K | 1.89M | 48.55M | — | — | — |
| Total Assets | 200.46M | 285.71M | 178.31M | 135.62M | 119.75M | 122.00M | 202.39M | 103.56M | 75.55M | 23.06M |
| Accounts Payable | 12.14M | 10.93M | 6.51M | 5.53M | 5.79M | 3.27M | 4.69M | 4.27M | 2.84M | 1.88M |
| Total Current Liabilities | 46.42M | 45.95M | 31.21M | 23.92M | 22.38M | 21.44M | 19.48M | 13.46M | 7.04M | 3.14M |
| Long-Term Debt | 122.21M | 121.73M | 98.55M | 97.54M | 0 | — | — | — | — | — |
| Total Liabilities | 305.93M | 294.51M | 243.52M | 224.98M | 111.33M | 25.65M | 22.09M | 13.46M | 7.04M | 6.75M |
| Shareholders' Equity | -105.47M | -8.80M | -65.21M | -89.36M | 8.41M | 96.36M | 180.30M | 90.09M | 68.52M | 16.31M |
| Retained Earnings | -959.72M | -806.22M | -679.35M | -577.10M | -467.32M | -356.50M | -228.02M | -122.87M | -47.21M | -27.21M |
| Total Debt | 122.21M | 121.73M | 98.55M | 97.54M | 0 | — | — | — | — | — |
| Net Cash (Debt) | 37.84M | 160.93M | 52.61M | 2.43M | 89.14M | 102.02M | 147.08M | 101.32M | 73.00M | 21.36M |
| Shares Outstanding | 48.35M | 42.23M | 32.49M | 23.13M | 22.46M | 22.17M | 21.03M | 16.21M | 13.75M | 2.31M |
This table shows 10 annual periods of UroGen Pharma's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow URGN's reporting calendar. What is a balance sheet?